Surrozen, Inc./DE
SRZN Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$27.28
KIRA · Stoqly’s AI analyst, in plain words
- Surrozen, Inc./DE had $3.5M of revenue in fiscal 2025, down 67.4% on the year before.
- Its operating margin was −1,210.6%, down 970.9 pts: of every 100 in sales, about −1,211 is left after running the business.
- Surrozen, Inc./DE lost $242M in fiscal 2025.
- Free cash flow was −$30.4M in fiscal 2025, −873.5% of revenue.
Market cap
$631M
P/E
—
Revenue
$3.5M
Net income
−$242M
Free cash flow
−$30.4M
Operating margin
−1,210.6%
Surrozen, Inc./DE in 30 seconds · fiscal 2025
Are sales growing?
−67.4%
No. Sales fell 67.4% last year.
Does it make a profit?
−6,960.8%
No. It lost money last year.
Does profit turn into cash?
−873.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Surrozen, Inc./DE does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 23, 2026
- Legal name
- Surrozen, Inc./DE
- CIK
- 0001824893
Surrozen, Inc./DE · SRZN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $12.5M | $0.0M | $10.7M | $3.5M |
| Revenue growth | — | — | −100.0% | — | −67.4% |
| Operating margin | — | −354.7% | — | −239.7% | −1,210.6% |
| Net income | −$54.6M | −$36.0M | −$43.0M | −$63.6M | −$242M |
| Net margin | — | −288.0% | — | −596.6% | −6,960.8% |
| Diluted EPS | −$2.21 | −$15.56 | −$21.33 | −$21.67 | −$32.37 |
| Cash | |||||
| Cash from operations | −$48.8M | −$44.1M | −$40.4M | −$17.6M | −$30.2M |
| Capital expenditure | $1.3M | $0.7M | $0.4M | $0.0M | $0.1M |
| Free cash flow | −$50.1M | −$44.9M | −$40.8M | −$17.7M | −$30.4M |
| FCF margin | — | −359.0% | — | −165.7% | −873.5% |
| Share buybacks | $0.0M | $2.6M | $0.0M | — | — |
| Share count change | −99.8% | −90.7% | −13.0% | 45.0% | 158.6% |
| Debt and strength | |||||
| Cash and short-term investments | $102M | $75.8M | $36.0M | $34.6M | $89.2M |
| Shareholders' equity | $110M | $76.0M | $37.9M | −$21.4M | −$188M |
| Current ratio | 7.7x | 8.4x | 5.8x | 5.3x | 9.2x |
| Returns and quality | |||||
| Return on equity | −69.6% | −38.8% | −75.6% | −767.9% | — |
| Return on tangible equity | −49.8% | −47.4% | −113.5% | — | — |
| Piotroski F-score | — | 3 | 2 | 2 | 2 |
| Altman Z'' | 2.5 | 1.3 | −12.6 | −18.8 | −15.5 |
Insiders bought, 12 months
$10.7M
6 insiders
Insiders sold, 12 months
$3.8M
4 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Surrozen, Inc./DE · SRZN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $27.28 a share, the company is worth $631M.
Source: SEC EDGAR XBRL filings (CIK 0001824893). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.